Dance Biopharm, Phillips-Medisize ink deal for inhaled insulin device

Privately-held biotech Dance Biopharm and Phillips-Medisize have entered into a joint development deal for a connected drug-delivery device for inhaled insulin.

The agreement gives Phillips-Medisize, which already designs and manufactures devices for Dance, the development work for future enhancements of Dance’s devices, as well as commercial manufacturing of the inhaled insulin delivery device when it gets to the market.

Get the full story at our sister site, Drug Delivery Business News.

The post Dance Biopharm, Phillips-Medisize ink deal for inhaled insulin device appeared first on MassDevice.

from MassDevice http://ift.tt/2iOcjmo